1736-1737 / 2605
0
RADCOMP
Re-irradiation:
➢
Considered strong indication.
➢
Multiple trials ongoing
➢
Issue: “cumulative dose of normal tissue” – how to deal with prior dose 1
year or 20 years ago (OAR dose constraint definition)
➢
Issue: Appropriate patient selection –i.e. who will benefit considering the
risks?
Example: Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):819-27.
Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam
therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival
outcomes.
McAvoy S1